lorazepam has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral lorazepam was tolerated by the patients, but all patients needed dose reduction due to some adverse effects." | 1.36 | Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. ( Amini, M; Ghavamzadeh, A; Hadjibabaie, M; Hamedani, R; Hamidieh, AA; Sadrai, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamidieh, AA | 1 |
| Hamedani, R | 1 |
| Hadjibabaie, M | 1 |
| Amini, M | 1 |
| Sadrai, S | 1 |
| Ghavamzadeh, A | 1 |
| Kopp, M | 1 |
| Holzner, B | 1 |
| Brugger, A | 1 |
| Nachbaur, D | 1 |
2 other studies available for lorazepam and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Dose-Response | 2010 |
Successful management of claustrophobia and depression during allogeneic SCT.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Cognitive Behavioral Therapy; Combined Modality Therapy; Cranio | 2001 |